Skip to main content
Publications
Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV, Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson R, Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med. 2024 Mar;30(3):650-9. doi: 10.1038/s41591-024-02827-9
Mareque M, Montesinos P, Font P, Guinea JM, De La Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Sauchelli S, Jimenez-Murcia S, Sanchez I, Riesco N, Custal N, Fernandez-Garcia JC, Garrido-Sanchez L, Tinahones FJ, Steiger H, Israel M, Banos RM, Botella C, de la Torre R, Fernandez-Real JM, Ortega FJ, Fruhbeck G, Granero R, Tarrega S, Crujeiras AB, Rodriguez A, Estivill X, Beckmann JS, Casanueva FF, Menchon JM, Fernandez-Aranda F. Orexin and sleep quality in anorexia nervosa: clinical relevance and influence on treatment outcome. Psychoneuroendocrinology. 2016 Mar;65:102-8. doi: 10.1016/j.psyneuen.2015.12.014